542 related articles for article (PubMed ID: 24525233)
1. A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer.
Jiao S; Wang H; Shi Z; Dong A; Zhang W; Song X; He F; Wang Y; Zhang Z; Wang W; Wang X; Guo T; Li P; Zhao Y; Ji H; Zhang L; Zhou Z
Cancer Cell; 2014 Feb; 25(2):166-80. PubMed ID: 24525233
[TBL] [Abstract][Full Text] [Related]
2. VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer.
Jiao S; Li C; Hao Q; Miao H; Zhang L; Li L; Zhou Z
Nat Commun; 2017 Jan; 8():14058. PubMed ID: 28051067
[TBL] [Abstract][Full Text] [Related]
3. Computational insights into the interaction mechanism of transcription cofactor vestigial-like protein 4 binding to TEA domain transcription factor 4 by molecular dynamics simulation and molecular mechanics generalized Born/surface area) calculation.
Gao J; Zhang Y; Chen H; Chen Q; Feng D; Zhang L; Li C
J Biomol Struct Dyn; 2019 Jul; 37(10):2538-2545. PubMed ID: 30051771
[TBL] [Abstract][Full Text] [Related]
4. VGLL4 inhibits EMT in part through suppressing Wnt/β-catenin signaling pathway in gastric cancer.
Li H; Wang Z; Zhang W; Qian K; Liao G; Xu W; Zhang S
Med Oncol; 2015 Mar; 32(3):83. PubMed ID: 25701461
[TBL] [Abstract][Full Text] [Related]
5. Cyclin-dependent kinase 1 (CDK1)-mediated mitotic phosphorylation of the transcriptional co-repressor Vgll4 inhibits its tumor-suppressing activity.
Zeng Y; Stauffer S; Zhou J; Chen X; Chen Y; Dong J
J Biol Chem; 2017 Sep; 292(36):15028-15038. PubMed ID: 28739871
[TBL] [Abstract][Full Text] [Related]
6. VGLL4 functions as a new tumor suppressor in lung cancer by negatively regulating the YAP-TEAD transcriptional complex.
Zhang W; Gao Y; Li P; Shi Z; Guo T; Li F; Han X; Feng Y; Zheng C; Wang Z; Li F; Chen H; Zhou Z; Zhang L; Ji H
Cell Res; 2014 Mar; 24(3):331-43. PubMed ID: 24458094
[TBL] [Abstract][Full Text] [Related]
7. The hippo pathway in human upper gastrointestinal dysplasia and carcinoma: a novel oncogenic pathway.
Lam-Himlin DM; Daniels JA; Gayyed MF; Dong J; Maitra A; Pan D; Montgomery EA; Anders RA
Int J Gastrointest Cancer; 2006; 37(4):103-9. PubMed ID: 18175224
[TBL] [Abstract][Full Text] [Related]
8. VGLL4 Selectively Represses YAP-Dependent Gene Induction and Tumorigenic Phenotypes in Breast Cancer.
Zhang Y; Shen H; Withers HG; Yang N; Denson KE; Mussell AL; Truskinovsky A; Fan Q; Gelman IH; Frangou C; Zhang J
Sci Rep; 2017 Jul; 7(1):6190. PubMed ID: 28733631
[TBL] [Abstract][Full Text] [Related]
9. Targeting Transcriptional Enhanced Associate Domains (TEADs).
Gibault F; Sturbaut M; Bailly F; Melnyk P; Cotelle P
J Med Chem; 2018 Jun; 61(12):5057-5072. PubMed ID: 29251924
[TBL] [Abstract][Full Text] [Related]
10. RNA interference mediated YAP gene silencing inhibits invasion and metastasis of human gastric cancer cell line SGC-7901.
Zhou Z; Zhu JS; Xu ZP
Hepatogastroenterology; 2011; 58(112):2156-61. PubMed ID: 22024089
[TBL] [Abstract][Full Text] [Related]
11. Dual function of VGLL4 in muscle regeneration.
Feng X; Wang Z; Wang F; Lu T; Xu J; Ma X; Li J; He L; Zhang W; Li S; Yang W; Zhang S; Ge G; Zhao Y; Hu P; Zhang L
EMBO J; 2019 Sep; 38(17):e101051. PubMed ID: 31328806
[TBL] [Abstract][Full Text] [Related]
12. DNA-binding mechanism of the Hippo pathway transcription factor TEAD4.
Shi Z; He F; Chen M; Hua L; Wang W; Jiao S; Zhou Z
Oncogene; 2017 Jul; 36(30):4362-4369. PubMed ID: 28368398
[TBL] [Abstract][Full Text] [Related]
13. VGLL4 with low YAP expression is associated with favorable prognosis in colorectal cancer.
Kim JY; Kim EK; Lee WM; Hong YO; Lee H
APMIS; 2020 Oct; 128(10):543-551. PubMed ID: 32794608
[TBL] [Abstract][Full Text] [Related]
14. The Tumor Suppressor Interferon Regulatory Factor 2 Binding Protein 2 Regulates Hippo Pathway in Liver Cancer by a Feedback Loop in Mice.
Feng X; Lu T; Li J; Yang R; Hu L; Ye Y; Mao F; He L; Xu J; Wang Z; Liu Y; Zhang Y; Ji H; Zhao Y; Cheng S; Tian W; Zhang L
Hepatology; 2020 Jun; 71(6):1988-2004. PubMed ID: 31538665
[TBL] [Abstract][Full Text] [Related]
15. VGLL4 is a transcriptional cofactor acting as a novel tumor suppressor via interacting with TEADs.
Deng X; Fang L
Am J Cancer Res; 2018; 8(6):932-943. PubMed ID: 30034932
[TBL] [Abstract][Full Text] [Related]
16. Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer.
Wang X; Su L; Ou Q
Eur J Cancer; 2012 May; 48(8):1227-34. PubMed ID: 22056638
[TBL] [Abstract][Full Text] [Related]
17. Loss of VGLL4 suppresses tumor PD-L1 expression and immune evasion.
Wu A; Wu Q; Deng Y; Liu Y; Lu J; Liu L; Li X; Liao C; Zhao B; Song H
EMBO J; 2019 Jan; 38(1):. PubMed ID: 30396996
[TBL] [Abstract][Full Text] [Related]
18. YAP is a candidate oncogene for esophageal squamous cell carcinoma.
Muramatsu T; Imoto I; Matsui T; Kozaki K; Haruki S; Sudol M; Shimada Y; Tsuda H; Kawano T; Inazawa J
Carcinogenesis; 2011 Mar; 32(3):389-98. PubMed ID: 21112960
[TBL] [Abstract][Full Text] [Related]
19. Expression of VGLL4 and YAP protein in gastric carcinoma tissues and tumor prognosis.
Han XY; Liu HZ; Cai CY; Li XQ; Ju YB; Li YY; Zhang ZG
Minerva Med; 2018 Dec; 109(6):429-435. PubMed ID: 29914241
[TBL] [Abstract][Full Text] [Related]
20. Depletion of VGLL4 Causes Perinatal Lethality without Affecting Myocardial Development.
Sheldon C; Farley A; Ma Q; Pu WT; Lin Z
Cells; 2022 Sep; 11(18):. PubMed ID: 36139407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
